Citation Impact
Citing Papers
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
2012
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma
2008
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
2016
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
2011
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Recent advances in the management of AL Amyloidosis
2015
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
How chemokines organize the tumour microenvironment
2023
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial
2015
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Cellular senescence: when bad things happen to good cells
2007 Standout
Recombinant TFPI and variants:potential implications in the treatment of cardiovascular disorders
1998
How many drug targets are there?
2006 Standout
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
2010
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Amyloid diseases of the heart: current and future therapies
2012
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Head and neck cancer
2008 Standout
The procoagulant potential of environmental particles (PM10)
2005
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Cancer stem cells revisited
2017 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
The Epigenomics of Cancer
2007 Standout
The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
2023
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Targeting macrophages: therapeutic approaches in cancer
2018
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
2015
Progress and problems in the exploration of therapeutic targets
2006
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
2006
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
Systemic amyloidosis
2015 Standout
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
2011
Emerging Biological Principles of Metastasis
2017 Standout
Can NF-κB be a target for novel and efficient anti-cancer agents?
2006
Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase
2003
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cell-cycle dysregulation and anticancer therapy
2003
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase
2004
Gut microbiota, metabolites and host immunity
2016 Standout
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
2009
Localization and activity of tissue factor in human aortic atherosclerotic lesions
1997
Neutrophils in cancer: neutral no more
2016 Standout
Immune cell promotion of metastasis
2015
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
Pro-angiogenic Activities of CYR61 (CCN1) Mediated through Integrins αvβ3 and α6β1 in Human Umbilical Vein Endothelial Cells
2002 Standout
Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
2015 StandoutNobel
A multi-targeted approach to treating bone metastases
2014
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
2016
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Molecular biology and targeted therapies for urothelial carcinoma
2015
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
2015
Incorporating Bortezomib into the Treatment of Lung Cancer
2007
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
2006
New and emerging HDAC inhibitors for cancer treatment
2014
Current Trends in Diagnosis and Management of Cardiac Amyloidosis
2013
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
2006
Transcriptional control of human p53-regulated genes
2008 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Histone Deacetylase Inhibitors: From Bench to Clinic
2008
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Activation of αVβ3 on Vascular Cells Controls Recognition of Prothrombin
1998
Investigation of Chronic Venous Insufficiency
2000 Standout
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
2016
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
2012
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies
2007
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Diverse Functions of Macrophages in Different Tumor Microenvironments
2018
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
2011
Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold
2009
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
2010
Works of Yusri Elsayed being referenced
A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
2013
Procoagulant Properties of Atherosclerotic Aortasa
1994
Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
2005
Expression of Tissue Factor and lnterleukin-1β in a Novel Rabbit Model of Disseminated Intravascular Coagulation Induced by Carrageenan and Lipopolysaccharide
1995
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
2011
Effects of Recombinant Human Tissue Factor Pathway Inhibitor on Thrombus Formation and ItsIn VivoDistribution in a Rat DIC Model
1996
Enhanced expression of tissue factor activity in the atherosclerotic aortas of cholesterol-fed rabbits
1996
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
2012
Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma
2012
Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)
2007
Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies
2006
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
2005
Signal Transduction–Directed Cancer Treatments
2003
Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
2014
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
2009
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
2009
Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies
2006
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
2001